Nuevas Tecnologías en el Mercado Financiero: Dinero Electrónico y el Crowdfunding. Entrevista al Dr. Miguel Morachimo Rodríguez

Las nuevas tecnologías han implicado un cambio en nuestras conductas dentro de la sociedad, dentro de ello la forma como utilizamos el mercado financiero. Así, actualmente las nuevas figuras como el Dinero Electrónico y Crowdfunding plantean nuevos retos a considerar.Al respecto, en nuestro país tenemos una reciente ley de Dinero Electrónico y la Superintendencia de Banca y Seguros emitió una alerta referida al uso de la figura del Crowdfunding como mecanismo de financiemiento, así el Dr. Morachimo nos explica la naturaleza de las presentes figuras y sus implicancias en nuestra legislación

Breves Reflexiones Constitucionales Sobre Temas de Actualidad. Entrevista a Gerardo Eto Cruz

En la presente entrevista, el Dr. Eto plantea su opinión acerca de diversos temas de actualidad, en lo cuales se ve involucrado el Derecho Constitucional. Así pues, la línea de la presente entrevista recorre diversos temas como la legitimidad de la Constitución de 1993, sus avances, retrocesos y retos pendientes. Asimismo, realiza breves comentarios sobre las garantías constitucionales incidiendo sobretodo en la acción de amparo; luego analiza temas diversos como la tenencia de armas, la ley de la promoción de la alimentación saludable (la mal llamada ley de la comida chatarra), así como el derecho sucesorio de las uniones de hecho

Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

International audienceIn this article, the name of the GLORIA-AF investigator Anastasios Kollias was given incorrectly as Athanasios Kollias in the Acknowledgements. The original article has been corrected

Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry

Background: Previous studies suggested potential ethnic differences in the management and outcomes of atrial fibrillation (AF). We aim to analyse oral anticoagulant (OAC) prescription, discontinuation, and risk of adverse outcomes in Asian patients with AF, using data from a global prospective cohort study. Methods: From the GLORIA-AF Registry Phase II-III (November 2011-December 2014 for Phase II, and January 2014-December 2016 for Phase III), we analysed patients according to their self-reported ethnicity (Asian vs. non-Asian), as well as according to Asian subgroups (Chinese, Japanese, Korean and other Asian). Logistic regression was used to analyse OAC prescription, while the risk of OAC discontinuation and adverse outcomes were analysed through Cox-regression model. Our primary outcome was the composite of all-cause death and major adverse cardiovascular events (MACE). The original studies were registered with ClinicalTrials.gov, NCT01468701, NCT01671007, and NCT01937377. Findings: 34,421 patients were included (70.0 ± 10.5 years, 45.1% females, 6900 (20.0%) Asian: 3829 (55.5%) Chinese, 814 (11.8%) Japanese, 1964 (28.5%) Korean and 293 (4.2%) other Asian). Most of the Asian patients were recruited in Asia (n = 6701, 97.1%), while non-Asian patients were mainly recruited in Europe (n = 15,449, 56.1%) and North America (n = 8378, 30.4%). Compared to non-Asian individuals, prescription of OAC and non-vitamin K antagonist oral anticoagulant (NOAC) was lower in Asian patients (Odds Ratio [OR] and 95% Confidence Intervals (CI): 0.23 [0.22-0.25] and 0.66 [0.61-0.71], respectively), but higher in the Japanese subgroup. Asian ethnicity was also associated with higher risk of OAC discontinuation (Hazard Ratio [HR] and [95% CI]: 1.79 [1.67-1.92]), and lower risk of the primary composite outcome (HR [95% CI]: 0.86 [0.76-0.96]). Among the exploratory secondary outcomes, Asian ethnicity was associated with higher risks of thromboembolism and intracranial haemorrhage, and lower risk of major bleeding. Interpretation: Our results showed that Asian patients with AF showed suboptimal thromboembolic risk management and a specific risk profile of adverse outcomes; these differences may also reflect differences in country-specific factors. Ensuring integrated and appropriate treatment of these patients is crucial to improve their prognosis. Funding: The GLORIA-AF Registry was funded by Boehringer Ingelheim GmbH